JP 1302 dihydrochloride

Pricing Availability   Qty
Cat.No. 2666 - JP 1302 dihydrochloride | C24H24N4.2HCl | CAS No. 1259314-65-2
Description: Potent and selective α2C antagonist
Chemical Name: N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine dihydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature

Biological Activity

α2C-adrenoceptor antagonist that displays ~ 50-fold selectivity over other α2-adrenoceptor subtypes (Ki values are 28, 1470, 1700 and 3150 nM for human α2C, α2B, α2D and α2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35GTPγS binding in vitro (KB = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo.

Technical Data

M. Wt 441.4
Formula C24H24N4.2HCl
Storage Desiccate at -20°C
Purity ≥99% (HPLC)
CAS Number 1259314-65-2
PubChem ID 49855035
InChI Key VVZOADYFJAJZGL-UHFFFAOYSA-N
Smiles CN(CC5)CCN5C(C=C4)=CC=C4NC2=C3C(C=CC=C3)=NC1=CC=CC=C12.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 2.2 5
water 44.14 100

Preparing Stock Solutions

The following data is based on the product molecular weight 441.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.27 mL 11.33 mL 22.66 mL
5 mM 0.45 mL 2.27 mL 4.53 mL
10 mM 0.23 mL 1.13 mL 2.27 mL
50 mM 0.05 mL 0.23 mL 0.45 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

Tricklebank (2007) JP-1302: a new tool to shed light on the roles of α2C-adrenoceptors in brain. Br.J.Pharmacol. 150 381 PMID: 17220912

Sallinen et al (2007) Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302. Br.J.Pharmacol. 150 391 PMID: 17220913


If you know of a relevant reference for JP 1302 dihydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Adrenergic α2 Receptor Antagonists

Keywords: JP 1302 dihydrochloride, JP 1302 dihydrochloride supplier, Potent, selective, α2C-adrenoceptor, alpha2C-adrenoceptors, α2c-adrenergic, alpha2c-adrenergic, a2c-adrenoceptor, antagonists, Receptors, JP1302, dihydrochloride, Adrenergic, Alpha-2, 2666, Tocris Bioscience

1 Citation for JP 1302 dihydrochloride

Citations are publications that use Tocris products. Selected citations for JP 1302 dihydrochloride include:

Jiang et al (2015) SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Mol Med Rep 18 PMID: 25522427


Do you know of a great paper that uses JP 1302 dihydrochloride from Tocris? Please let us know.

Reviews for JP 1302 dihydrochloride

There are currently no reviews for this product. Be the first to review JP 1302 dihydrochloride and earn rewards!

Have you used JP 1302 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.